article thumbnail

Alnylam change to heart drug trial sparks doubts, sinking shares

BioPharma Drive: Drug Pricing

Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.

article thumbnail

EyePoint sees stock surge on AMD drug trial data

BioPharma Drive: Drug Pricing

The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was "non-inferior" to Regeneron's Eylea.

article thumbnail

BridgeBio claims success in heart drug trial, rebounding from earlier failure

BioPharma Drive: Drug Pricing

The results come about two years after negative findings from an earlier phase of the study, and position the company to seek an approval in transthyretin amyloidosis cardiomyopathy.

article thumbnail

ASH23: CAR-T for autoimmune disease, real-world questions and sickle cell’s social media mentions

BioPharma Drive: Drug Pricing

Study results disclosed at the American Society of Hematology meeting Saturday suggested potential for cell therapy in lupus and pointed out drug trial limitations.

article thumbnail

Newer Diabetes Meds Might Not Work as Well in Black Patients

Drugs.com

22, 2023 – New research suggests some newer diabetes treatments may not be as beneficial for Black patients, after earlier drug trials included small numbers of non-white people. FRIDAY, Sept. Whether the medications -- called sodium-glucose.

article thumbnail

Merck Drops Late-Stage Cancer Drug Trial Due to Disappointing Efficacy | 2021-01-20

The Pharma Data

Drug Industry Daily (DID) the premier online resource for savvy pharmaceutical professionals whose jobs depend on accurate knowledge about the daily activities of Congress, the FDA, other key regulators … and what their competitors are up to.

article thumbnail

aTyr Pharma Finishes Enrollment of Respiratory Drug Trial for COVID-19 Patients | 2020-10-27

The Pharma Data

based aTyr Pharma has finalized enrollment for a phase 2 trial to evaluate an investigational anti-inflammatory drug in COVID-19 patients with severe respiratory complications. San Diego, Calif.-based ATYR1923 is meant to reduce inflammation and restore the lung’s immune balance.

Trials 52